Acalabrutinib
- Generic Name
- Acalabrutinib
- Brand Names
- Calquence
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23N7O2
- CAS Number
- 1420477-60-6
- Unique Ingredient Identifier
- I42748ELQW
- Background
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others.
...
- Indication
Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy. It has also been recently approved for chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma (MCL), Small Lymphocytic Lymphoma
- Associated Therapies
- -
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 155
- Registration Number
- NCT04075292
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 552
- Registration Number
- NCT04008706
- Locations
- 🇬🇧
Research Site, Newmarket, United Kingdom
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 132
- Registration Number
- NCT04002947
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
- Conditions
- Interventions
- First Posted Date
- 2019-05-30
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 16
- Registration Number
- NCT03968848
- Locations
- 🇺🇸
Research Site, Knoxville, Tennessee, United States
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03946878
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT03932331
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- University of Birmingham
- Target Recruit Count
- 105
- Registration Number
- NCT03899337
- Locations
- 🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom
🇬🇧University College London Hospital, London, United Kingdom
🇬🇧University Hospital of Wales, Cardiff, United Kingdom
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2023-12-04
- Lead Sponsor
- Rigshospitalet, Denmark
- Target Recruit Count
- 212
- Registration Number
- NCT03868722
- Locations
- 🇸🇪
Örebro University Hospital, Örebro, Sweden
🇸🇪Karolinska University Hospital, Stockholm, Sweden
🇩🇰Herlev og Gentofte Hospital, Herlev, Denmark
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 35
- Registration Number
- NCT03863184
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
- Conditions
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 984
- Registration Number
- NCT03836261
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.